BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 22180434)

  • 21. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
    Argiris A; Seropian S; Cooper DL
    Ann Oncol; 2000 Jun; 11(6):665-72. PubMed ID: 10942053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.
    Jabbour E; Peslin N; Arnaud P; Ferme C; Carde P; Vantelon JM; Bocaccio C; Bourhis JH; Koscielny S; Ribrag V
    Leuk Lymphoma; 2005 Jun; 46(6):861-7. PubMed ID: 16019530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients.
    Chopra R; McMillan AK; Linch DC; Yuklea S; Taghipour G; Pearce R; Patterson KG; Goldstone AH
    Blood; 1993 Mar; 81(5):1137-45. PubMed ID: 8443375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.
    Czyz A; Lojko-Dankowska A; Dytfeld D; Nowicki A; Gil L; Matuszak M; Kozlowska-Skrzypczak M; Kazmierczak M; Bembnista E; Komarnicki M
    Med Oncol; 2013; 30(3):611. PubMed ID: 23702734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience.
    Rassy E; Danu A; Ibrahim T; Lazarovici J; Ghez D; Michot JM; Arfi-Rouche J; Rossignol J; Vergé V; Dartigues P; Ribrag V
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e373-e380. PubMed ID: 33277224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas.
    Sapelli J; Filho JS; Matias Vieira GM; Moura FL; Germano JN; de Lima VCC
    Leuk Res; 2021 Nov; 110():106689. PubMed ID: 34592699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy.
    Bierman PJ; Anderson JR; Freeman MB; Vose JM; Kessinger A; Bishop MR; Armitage JO
    Ann Oncol; 1996 Feb; 7(2):151-6. PubMed ID: 8777171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
    Sirohi B; Cunningham D; Powles R; Murphy F; Arkenau T; Norman A; Oates J; Wotherspoon A; Horwich A
    Ann Oncol; 2008 Jul; 19(7):1312-1319. PubMed ID: 18356139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.
    Xin X; Lin L; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Meng F; Cao Y; Zhu X; Zhang Y
    Cytotherapy; 2024 May; 26(5):456-465. PubMed ID: 38385909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma.
    Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
    Leuk Lymphoma; 2000 Mar; 37(1-2):185-7. PubMed ID: 10721785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
    Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
    Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
    Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
    Ann Oncol; 2006 May; 17 Suppl 4():iv25-30. PubMed ID: 16702181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
    Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
    Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.
    Nademanee A; O'Donnell MR; Snyder DS; Schmidt GM; Parker PM; Stein AS; Smith EP; Molina A; Stepan DE; Somlo G
    Blood; 1995 Mar; 85(5):1381-90. PubMed ID: 7858268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
    Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF
    Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
    Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
    Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.
    Torjman L; Ladeb S; Lakhal A; Ben Othman T; Abdelkefi A; Ben Abdeladhim A
    Tunis Med; 2007 Jan; 85(1):35-8. PubMed ID: 17424707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.